Walleye Trading’s Stoke Therapeutics STOK Stock Holding History

Walleye Trading’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$39K	–	5533
2021 Q1	$39K	Buy	+1,000	New	+$56.9K	﹤0.01%	4406

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Walleye Trading's STOK Position: Q2 2021 in Review

Walleye Trading sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 7,900 shares — an estimated $307K sold.

Walleye Trading first reported a position in STOK in Q1 2021 and held it in 1 quarter. The position peaked at $307K in Q1 2021. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

Walleye Trading reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
Walleye Trading sold 7,900 Stoke Therapeutics shares in Q2 2021, an estimated $307K.
Walleye Trading first reported a position in Stoke Therapeutics in Q1 2021 and held it in 1 quarter.
Walleye Trading's Stoke Therapeutics position peaked at $307K in Q1 2021.
97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Walleye Trading's 13F filing for Q2 2021, filed 16 Aug 2021.